Does hepatic impairment affect the pharmacokinetics and pharmacodynamics of a single 10 mg dose of rivaroxaban?
Moderate hepatic impairment significantly increases rivaroxaban exposure and pharmacodynamic effects after a single 10 mg dose, whereas mild impairment does not.
Moderate (but not mild) hepatic impairment reduced total body clearance of rivaroxaban after a single 10 mg dose, leading to increased rivaroxaban exposure and pharmacodynamic effects.
Kubitza et al. (2013) studied this question.